Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)
Peters, S., Shaw, A.T., Besse, B., Felip, E., Solomon, B.J., Soo, R.A., Bearz, A., Gadgee, S.M., Lin, C.-C., Kao, S., Seto, T., Masters, E.T., Abbattista, A., Clancy, J.S., Thurm, H., Reisman, A., Camidge, D.R.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article